FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378594> ?p ?o ?g. }

• W4308378594 abstract "<h3>Background</h3> The emergence of antibodies targeting checkpoint modulators such as PD-1 and CTLA-4 has revolutionized solid tumor treatment and highlighted the importance of effectively engaging the immune system to drive durable responses. However, well over 50% of solid tumor patients do not respond adequately to checkpoint modulators; due to generally ascribed active immune suppression in the tumor microenvironment (TME). To overcome suppression and increase tumor control, we developed a highly selective and precisely tuned Chimeric Antigen Receptor (CAR), which targets Fibroblast Activating Protein (FAP)) expressed on both tumor cells and immune-suppressive Cancer Associated Fibroblasts (CAFs). This novel allogeneic CAR-iNKT cell (invariant natural killer T cell) product is IL-15 secreting, in addition to being FAP binding, and is intended for treatment of solid tumors. iNKT cells were selected as hosts due to their natural resistance to exhaustion, tissue homing properties, selective cytotoxicity towards M2 macrophages and stimulation of dendritic cell maturation properties which are essential for effective solid tumor directed therapies. In addition, iNKT cells have intrinsic CD1d- and NK receptor ligand targeted cytotoxicity, while not causing Graft <i>versus</i> Host Disease due to the presence of invariant T cell receptors. <h3>Methods</h3> Our proprietary CARDIS^TM platform combines screening of highly diverse (>10¹⁰) fully human scFv libraries with library-based direct functional selection in CAR format using mammalian display. Candidates can be further optimized using affinity tuning to ensure optimal and highly selective on-target/on-tumor activity and full mouse cross-reactivity. We developed a scalable manufacturing approach to engineer and specifically expand CAR and soluble IL-15-expressing allogeneic iNKT cells. <h3>Results</h3> Using our CARDIS^TM platform, we generated a panel of fully human, potent, and highly selective anti-human FAP CARs with equivalent cross-reactivity towards mouse FAP. In xenograft mouse models our FAP-CAR-IL-15 iNKT cells effectively control FAP-expressing tumors, as well as FAP negative tumors with immune-suppressive stroma mediated by FAP+ CAFs<i>,</i> while soluble IL-15 prolongs persistence in immunocompromised mice. In addition, we show that FAP-CAR-IL-15 iNKT cells mediate the infiltration of tumor-specific T-cells and enhance their anti-tumor activity. <h3>Conclusions</h3> We have used our CARDIS^TM and iNKT platforms to develop a CAR-iNKT therapy effectively and selectively targeting FAP positive tumor cells and suppressive CAF subsets in the TME. We believe that combining the activity of our FAP-CAR with the potent natural activity of iNKT cells will enable a level of tumor control and immune engagement to solid tumor patients beyond currently available treatments." @default.
• W4308378594 created "2022-11-11" @default.
• W4308378594 creator A5001895446 @default.
• W4308378594 creator A5003962263 @default.
• W4308378594 creator A5005178144 @default.
• W4308378594 creator A5005528074 @default.
• W4308378594 creator A5018302338 @default.
• W4308378594 creator A5018392234 @default.
• W4308378594 creator A5022301880 @default.
• W4308378594 creator A5031142001 @default.
• W4308378594 creator A5032317765 @default.
• W4308378594 creator A5033443038 @default.
• W4308378594 creator A5042588975 @default.
• W4308378594 creator A5051952723 @default.
• W4308378594 creator A5072633053 @default.
• W4308378594 creator A5083307426 @default.
• W4308378594 creator A5084452579 @default.
• W4308378594 creator A5085528137 @default.
• W4308378594 creator A5089513015 @default.
• W4308378594 date "2022-11-01" @default.
• W4308378594 modified "2023-10-14" @default.
• W4308378594 title "358 Development of an allogenic FAP CAR iNKT product to target tumor stroma and modulate the tumor microenvironment" @default.
• W4308378594 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0358" @default.
• W4308378594 hasPublicationYear "2022" @default.
• W4308378594 type Work @default.
• W4308378594 citedByCount "0" @default.
• W4308378594 crossrefType "proceedings-article" @default.
• W4308378594 hasAuthorship W4308378594A5001895446 @default.
• W4308378594 hasAuthorship W4308378594A5003962263 @default.
• W4308378594 hasAuthorship W4308378594A5005178144 @default.
• W4308378594 hasAuthorship W4308378594A5005528074 @default.
• W4308378594 hasAuthorship W4308378594A5018302338 @default.
• W4308378594 hasAuthorship W4308378594A5018392234 @default.
• W4308378594 hasAuthorship W4308378594A5022301880 @default.
• W4308378594 hasAuthorship W4308378594A5031142001 @default.
• W4308378594 hasAuthorship W4308378594A5032317765 @default.
• W4308378594 hasAuthorship W4308378594A5033443038 @default.
• W4308378594 hasAuthorship W4308378594A5042588975 @default.
• W4308378594 hasAuthorship W4308378594A5051952723 @default.
• W4308378594 hasAuthorship W4308378594A5072633053 @default.
• W4308378594 hasAuthorship W4308378594A5083307426 @default.
• W4308378594 hasAuthorship W4308378594A5084452579 @default.
• W4308378594 hasAuthorship W4308378594A5085528137 @default.
• W4308378594 hasAuthorship W4308378594A5089513015 @default.
• W4308378594 hasBestOaLocation W43083785941 @default.
• W4308378594 hasConcept C147483822 @default.
• W4308378594 hasConcept C151872237 @default.
• W4308378594 hasConcept C18903297 @default.
• W4308378594 hasConcept C203014093 @default.
• W4308378594 hasConcept C2776107976 @default.
• W4308378594 hasConcept C2777701055 @default.
• W4308378594 hasConcept C2780674031 @default.
• W4308378594 hasConcept C3875195 @default.
• W4308378594 hasConcept C502942594 @default.
• W4308378594 hasConcept C86803240 @default.
• W4308378594 hasConcept C8891405 @default.
• W4308378594 hasConcept C95444343 @default.
• W4308378594 hasConceptScore W4308378594C147483822 @default.
• W4308378594 hasConceptScore W4308378594C151872237 @default.
• W4308378594 hasConceptScore W4308378594C18903297 @default.
• W4308378594 hasConceptScore W4308378594C203014093 @default.
• W4308378594 hasConceptScore W4308378594C2776107976 @default.
• W4308378594 hasConceptScore W4308378594C2777701055 @default.
• W4308378594 hasConceptScore W4308378594C2780674031 @default.
• W4308378594 hasConceptScore W4308378594C3875195 @default.
• W4308378594 hasConceptScore W4308378594C502942594 @default.
• W4308378594 hasConceptScore W4308378594C86803240 @default.
• W4308378594 hasConceptScore W4308378594C8891405 @default.
• W4308378594 hasConceptScore W4308378594C95444343 @default.
• W4308378594 hasLocation W43083785941 @default.
• W4308378594 hasOpenAccess W4308378594 @default.
• W4308378594 hasPrimaryLocation W43083785941 @default.
• W4308378594 hasRelatedWork W2499376085 @default.
• W4308378594 hasRelatedWork W2519433597 @default.
• W4308378594 hasRelatedWork W2804415345 @default.
• W4308378594 hasRelatedWork W3025154575 @default.
• W4308378594 hasRelatedWork W3134152892 @default.
• W4308378594 hasRelatedWork W3198713608 @default.
• W4308378594 hasRelatedWork W4226283103 @default.
• W4308378594 hasRelatedWork W4281389645 @default.
• W4308378594 hasRelatedWork W4286629873 @default.
• W4308378594 hasRelatedWork W4378715746 @default.
• W4308378594 isParatext "false" @default.
• W4308378594 isRetracted "false" @default.
• W4308378594 workType "article" @default.